Soluble CD40 ligand directly alters glomerular permeability and may act as a circulating permeability factor in FSGS

PLoS ONE

Volumn 12, Issue 11, 2017, Pages

  Doublier, Sophie ^a   Zennaro, Cristina ^b   Musante, Luca ^c   Spatola, Tiziana ^a   Candiano, Giovanni ^c   Bruschi, Maurizio ^c   Besso, Luca ^a   Cedrino, Massimo ^a   Carraro, Michele ^b   Ghiggeri, Gian Marco ^c   Camussi, Giovanni ^a   Lupia, Enrico ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TRIESTE   (Italy)

^c G GASLINI INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CALCINEURIN INHIBITOR; CD40 LIGAND; CREATININE; NEPHRIN; PODOCIN; PROTEIN; VASCULOTROPIN; ALBUMINOID; CD40 ANTIGEN; CORTICOSTEROID; CYTOTOXIN; HEMODIALYSIS FLUID; MEMBRANE PROTEIN; SIGNAL PEPTIDE;

ADOLESCENT; ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL MEMBRANE; CHILD; CONGENITAL NEPHROTIC SYNDROME; CONTROLLED STUDY; CREATININE URINE LEVEL; EPITHELIUM CELL; FEMALE; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS; GLOMERULUS EPITHELIUM; GLOMERULUS FILTRATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; KIDNEY BIOPSY; MAJOR CLINICAL STUDY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; MOUSE; NEPHROTIC SYNDROME; NONHUMAN; PATHOGENESIS; PLASMA EXCHANGE; PLASMA FACTOR; PLASMAPHERESIS; PODOCYTE; PRESCHOOL CHILD; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN URINE LEVEL; PROTEINURIA; RAT; RECURRENT DISEASE; SCHOOL CHILD; STEROID SENSITIVE NEPHROTIC SYNDROME; WESTERN BLOTTING; ANIMAL; CELL MEMBRANE PERMEABILITY; CHEMISTRY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; KIDNEY TRANSPLANTATION; METABOLISM; PATHOLOGY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ADULT; ALBUMINS; ANIMALS; CD40 ANTIGENS; CD40 LIGAND; CELL MEMBRANE; CELL MEMBRANE PERMEABILITY; CHILD; CHILD, PRESCHOOL; CYTOTOXINS; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION REGULATION; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEMODIALYSIS SOLUTIONS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY GLOMERULUS; KIDNEY TRANSPLANTATION; MALE; MEMBRANE PROTEINS; MICE; NEPHROTIC SYNDROME; PLASMA EXCHANGE; PLASMAPHERESIS; RATS;

EID: 85034784011     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0188045     Document Type: Article

References (63)

1. Quezada SA, Jarvinen LZ, Lind EF, Noelle RJ. CD40/CD154 interactions at the interface of tolerance and immunity. Annu Rev Immunol. 2004; 22:307–28. Epub 2004/03/23. https://doi.org/10.1146/annurev.immunol.22.012703.104533 PMID: 15032580.
2. Antoniades C, Bakogiannis C, Tousoulis D, Antonopoulos AS, Stefanadis C. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol. 2009; 54(8):669–77. Epub 2009/08/15. S0735-1097(09)01789-6 [pii] https://doi.org/10.1016/j.jacc.2009.03.076 PMID: 19679244.
3. Hassan GS, Merhi Y, Mourad W. CD40 ligand: a neo-inflammatory molecule in vascular diseases. Immunobiology. 2012; 217(5):521–32. Epub 2011/05/03 S0171-2985(11)00068-4 [pii] https://doi.org/10.1016/j.imbio.2011.03.010 PMID: 21529993.
4. Zhang B, Wu T, Chen M, Zhou Y, Yi D, Guo R. The CD40/CD40L system: a new therapeutic target for disease. Immunol Lett. 2013; 153(1–2):58–61. Epub 2013/07/31. S0165-2478(13)00097-7 [pii] https://doi.org/10.1016/j.imlet.2013.07.005 PMID: 23892087.
5. Esposito P, Grosjean F, Rampino T, Libetta C, Gregorini M, Fasoli G, et al. Costimulatory pathways in kidney transplantation: pathogenetic role, clinical significance and new therapeutic opportunities. Int Rev Immunol. 2014; 33(3):212–33. Epub 2013/10/17. https://doi.org/10.3109/08830185.2013.829470 PMID: 24127878.
6. Ruth AJ, Kitching AR, Semple TJ, Tipping PG, Holdsworth SR. Intrinsic renal cell expression of CD40 directs Th1 effectors inducing experimental crescentic glomerulonephritis. J Am Soc Nephrol. 2003; 14 (11):2813–22. Epub 2003/10/22. PMID: 14569091.
7. Reynolds J, Khan SB, Allen AR, Benjamin CD, Pusey CD. Blockade of the CD154-CD40 costimulatory pathway prevents the development of experimental autoimmune glomerulonephritis. Kidney Int. 2004; 66(4):1444–52. Epub 2004/10/02. https://doi.org/10.1111/j.1523-1755.2004.00907.x PMID: 15458437.
8. Lee VW, Qin X, Wang Y, Zheng G, Ince J, Tan TK, et al. The CD40-CD154 co-stimulation pathway mediates innate immune injury in adriamycin nephrosis. Nephrol Dial Transplant. 2010; 25(3):717–30. Epub 2009/11/06. gfp569 [pii] https://doi.org/10.1093/ndt/gfp569 PMID: 19889873.
9. Kairaitis L, Wang Y, Zheng L, Tay YC, Wang Y, Harris DC. Blockade of CD40-CD40 ligand protects against renal injury in chronic proteinuric renal disease. Kidney Int. 2003; 64(4):1265–72. Epub 2003/ 09/13. https://doi.org/10.1046/j.1523-1755.2003.00223.x PMID: 12969144.
10. Tanaka T, Kuroiwa T, Ikeuchi H, Ota F, Kaneko Y, Ueki K, et al. Human platelets stimulate mesangial cells to produce monocyte chemoattractant protein-1 via the CD40/CD40 ligand pathway and may amplify glomerular injury. J Am Soc Nephrol. 2002; 13(10):2488–96. Epub 2002/09/20. PMID: 12239237.
11. Laxmanan S, Datta D, Geehan C, Briscoe DM, Pal S. CD40: a mediator of pro- and anti-inflammatory signals in renal tubular epithelial cells. J Am Soc Nephrol. 2005; 16(9):2714–23. Epub 2005/07/22. ASN.2005010045 [pii] https://doi.org/10.1681/ASN.2005010045 PMID: 16033859.
12. Castellano G, Cappiello V, Fiore N, Pontrelli P, Gesualdo L, Schena FP, et al. CD40 ligand increases complement C3 secretion by proximal tubular epithelial cells. J Am Soc Nephrol. 2005; 16(7):2003–11. Epub 2005/05/06. ASN.2002120972 [pii] https://doi.org/10.1681/ASN.2002120972 PMID: 15872081.
13. Deambrosis I, Scalabrino E, Deregibus MC, Camussi G, Bussolati B. CD40-dependent activation of phosphatidylinositol 3-kinase/AKT pathway inhibits apoptosis of human cultured mesangial cells induced by oxidized LDL. Int J Immunopathol Pharmacol. 2005; 18(2):327–37. Epub 2005/05/13. 15 [pii]. PubMed https://doi.org/10.1177/039463200501800215 PMID: 15888255.
14. Delville M, Sigdel TK, Wei C, Li J, Hsieh SC, Fornoni A, et al. A circulating antibody panel for pretrans-plant prediction of FSGS recurrence after kidney transplantation. Sci Transl Med. 2014; 6 (256):256ra136. Epub 2014/10/03. 6/256/256ra136 [pii] https://doi.org/10.1126/scitranslmed.3008538 PMID: 25273097.
15. Rigothier C, Daculsi R, Lepreux S, Auguste P, Villeneuve J, Dewitte A, et al. CD154 Induces Matrix Metalloproteinase-9 Secretion in Human Podocytes. J Cell Biochem. 2016; 117(12):2737–47. Epub 2016/04/14. https://doi.org/10.1002/jcb.25571 PMID: 27070919.
16. Ripoll E, Pluvinet R, Torras J, Olivar R, Vidal A, Franquesa M, et al. In vivo therapeutic efficacy of intra-renal CD40 silencing in a model of humoral acute rejection. Gene therapy. 2011; 18(10):945–52. Epub 2011/04/08. https://doi.org/10.1038/gt.2011.39 PMID: 21472009.
17. Kuo HL, Huang CC, Lin TY, Lin CY. IL-17 and CD40 ligand synergistically stimulate the chronicity of diabetic nephropathy. Nephrol Dial Transplant. 2017. Epub 2017 Mar 1. https://doi.org/10.1093/ndt/gfw397 PMID: 28339909
18. Savin VJ, Sharma R, Sharma M, McCarthy ET, Swan SK, Ellis E, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med. 1996; 334(14):878–83. Epub 1996/04/04. https://doi.org/10.1056/NEJM199604043341402PMID: 8596570.
19. Candiano G, Musante L, Carraro M, Faccini L, Campanacci L, Zennaro C, et al. Apolipoproteins prevent glomerular albumin permeability induced in vitro by serum from patients with focal segmental glomerulosclerosis. J Am Soc Nephrol. 2001; 12(1):143–50. Epub 2001/01/03. PMID: 11134260.
20. Savin VJ, McCarthy ET, Sharma M. Permeability factors in focal segmental glomerulosclerosis. Semin Nephrol. 2003; 23(2):147–60. Epub 2003/04/22. https://doi.org/10.1053/snep.2003.50024 PMID: 12704575.
21. Glassock RJ. Circulating permeability factors in the nephrotic syndrome: a fresh look at an old problem. J Am Soc Nephrol. 2003; 14(2):541–3. Epub 2003/01/23. PMID: 12538757.
22. Jefferson JA, Shankland SJ. Has the circulating permeability factor in primary FSGS been found? Kidney Int. 2013; 84(2):235–8. Epub 2013/08/02. ki2013204 [pii] https://doi.org/10.1038/ki.2013.204 PMID: 23903418.
23. Wada T, Nangaku M. A circulating permeability factor in focal segmental glomerulosclerosis: the hunt continues. Clin Kidney J. 2015; 8(6):708–15. Epub 2015/11/28. https://doi.org/10.1093/ckj/sfv090 PMID: 26613029.
24. Davin JC. The glomerular permeability factors in idiopathic nephrotic syndrome. Pediatr Nephrol. 2016; 31(2):207–15. Epub 2015/05/01. https://doi.org/10.1007/s00467-015-3082-x PMID: 25925039.
25. Maas RJ, Deegens JK, Wetzels JF. Permeability factors in idiopathic nephrotic syndrome: historical perspectives and lessons for the future. Nephrol Dial Transplant. 2014; 29(12):2207–16. Epub 2014/11/ 25. gfu355 [pii] https://doi.org/10.1093/ndt/gfu355 PMID: 25416821.
26. Vincenti F, Ghiggeri GM. New insights into the pathogenesis and the therapy of recurrent focal glomerulosclerosis. Am J Transplant. 2005; 5(6):1179–85. Epub 2005/05/13. AJT968 [pii] https://doi.org/10.1111/j.1600-6143.2005.00968.x PMID: 15888021.
27. McCarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol. 2010; 5(11):2115–21. Epub 2010/10/ 23. CJN.03800609 [pii] https://doi.org/10.2215/CJN.03800609 PMID: 20966123.
28. Reiser J, Nast CC, Alachkar N. Permeability factors in focal and segmental glomerulosclerosis. Adv Chronic Kidney Dis. 2010; 21(5):417–21. Epub 2014/08/30. S1548-5595(14)00098-6 [pii] https://doi.org/10.1053/j.ackd.2014.05.010 PMID: 25168830.
29. Savin VJ, Sharma M, Zhou J, Genochi D, Sharma R, Srivastava T, et al. Multiple Targets for Novel Therapy of FSGS Associated with Circulating Permeability Factor. Biomed Res Int. 2017; 2017:6232616. Epub 2017/09/28. https://doi.org/10.1155/2017/6232616 PMID: 28951873.
30. Conaldi PG, Biancone L, Bottelli A, De Martino A, Camussi G, Toniolo A. Distinct pathogenic effects of group B coxsackieviruses on human glomerular and tubular kidney cells. J Virol. 1997; 71(12):9180–7. Epub 1997/11/26. PMID: 9371576.
31. Conaldi PG, Biancone L, Bottelli A, Wade-Evans A, Racusen LC, Boccellino M, et al. HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and Fas upregulation. J Clin Invest. 1998; 102(12):2041–9. Epub 1998/12/17. https://doi.org/10.1172/JCI3480 PMID: 9854039.
32. Zennaro C, Rastaldi MP, Bakeine GJ, Delfino R, Tonon F, Farra R, et al. A nanoporous surface is essential for glomerular podocyte differentiation in three-dimensional culture. International journal of nanomedicine. 2016; 11:4957–73. Epub 2016/10/21. https://doi.org/10.2147/IJN.S110201 PMID: 27757030; PubMed Central PMCID: PMC5053378.
33. Doublier S, Musante L, Lupia E, Candiano G, Spatola T, Caridi G, et al. Direct effect of plasma permeability factors from patients with idiopatic FSGS on nephrin and podocin expression in human podocytes. Int J Mol Med. 2005; 16(1):49–58. Epub 2005/06/09. PMID: 15942677.
34. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72:248–54. Epub 1976/05/07. S0003269776699996 [pii] PMID: 942051.
35. Doublier S, Ruotsalainen V, Salvidio G, Lupia E, Biancone L, Conaldi PG, et al. Nephrin redistribution on podocytes is a potential mechanism for proteinuria in patients with primary acquired nephrotic syndrome. Am J Pathol. 2001; 158(5):1723–31. Epub 2001/05/05. S0002-9440(10)64128-4 [pii] https://doi.org/10.1016/S0002-9440(10)64128-4 PMID: 11337370.
36. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ. CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ Res. 2003; 92(9):1041–8. Epub 2003/04/ 05. https://doi.org/10.1161/01.RES.0000070111.98158.6C PMID: 12676820.
37. Yang X, Ye R, Kong Q, Yang Q, Dong X, Yu X. CD40 is expressed on rat peritoneal mesothelial cells and upregulates ICAM-1 production. Nephrol Dial Transplant. 2004; 19(6):1378–84. Epub 2004/04/08. https://doi.org/10.1093/ndt/gfh144 PMID: 15069176.
38. Klein D, Barbe-Tuana F, Pugliese A, Ichii H, Garza D, Gonzalez M, et al. A functional CD40 receptor is expressed in pancreatic beta cells. Diabetologia. 2005; 48(2):268–76. Epub 2005/02/04. https://doi.org/10.1007/s00125-004-1645-7 PMID: 15690148.
39. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, et al. Nephrin expression is reduced in human diabetic nephropathy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes. 2003; 52(4):1023–30. Epub 2003/03/29. PMID: 12663475.
40. Savin VJ, Sharma R, Lovell HB, Welling DJ. Measurement of albumin reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol. 1992; 3(6):1260–9. Epub 1992/12/01. PMID: 1477322.
41. Dantal J, Bigot E, Bogers W, Testa A, Kriaa F, Jacques Y, et al. Effect of plasma protein adsorption on protein excretion in kidney-transplant recipients with recurrent nephrotic syndrome. N Engl J Med. 1994; 330(1):7–14. Epub 1994/01/06. https://doi.org/10.1056/NEJM199401063300102 PMID: 8259160.
42. Sharma M, Sharma R, McCarthy ET, Savin VJ. "The FSGS factor:" enrichment and in vivo effect of activity from focal segmental glomerulosclerosis plasma. J Am Soc Nephrol. 1999; 10(3):552–61. Epub 1999/03/12. PMID: 10073606.
43. Heslan JM, Branellec A, Laurent J, Lagrue G. The vascular permeability factor is a T lymphocyte product. Nephron. 1986; 42(2):187–8. Epub 1986/01/01. PMID: 3484808.
44. Kim EY, Roshanravan H, Dryer SE. Changes in podocyte TRPC channels evoked by plasma and sera from patients with recurrent FSGS and by putative glomerular permeability factors. Biochim Biophys Acta. 2017; 1863(9):2342–54. Epub 2017/06/21. S0925-4439(17)30205-3 [pii] https://doi.org/10.1016/j.bbadis.2017.06.010 PMID: 28629718.
45. Lee HS. Mechanisms and consequences of TGF-ss overexpression by podocytes in progressive podocyte disease. Cell Tissue Res. 2012; 347(1):129–40. Epub 2011/05/05. https://doi.org/10.1007/s00441-011-1169-7 PMID: 21541658.
46. Lennon R, Singh A, Welsh GI, Coward RJ, Satchell S, Ni L, et al. Hemopexin induces nephrin-dependent reorganization of the actin cytoskeleton in podocytes. J Am Soc Nephrol. 2008; 19(11):2140–9. Epub 2008/08/30. ASN.2007080940 [pii] https://doi.org/10.1681/ASN.2007080940 PMID: 18753258.
47. Wei C, El Hindi S, Li J, Fornoni A, Goes N, Sageshima J, et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med. 2011; 17(8):952–60. Epub 2011/08/02. nm.2411 [pii] https://doi.org/10.1038/nm.2411 PMID: 21804539.
48. Cathelin D, Placier S, Ploug M, Verpont MC, Vandermeersch S, Luque Y, et al. Administration of recombinant soluble urokinase receptor per se is not sufficient to induce podocyte alterations and proteinuria in mice. J Am Soc Nephrol. 2014; 25(8):1662–8. Epub 2014/05/03. ASN.2013040425 [pii] https://doi.org/10.1681/ASN.2013040425 PMID: 24790179.
49. Trimarchi H. Primary focal and segmental glomerulosclerosis and soluble factor urokinase-type plas-minogen activator receptor. World J Nephrol. 2(4):103–10. Epub 2013/11/21. https://doi.org/10.5527/wjn.v2.i4.103 PMID: 24255893.
50. Shankland SJ, Pollak MR. A suPAR circulating factor causes kidney disease. Nat Med. 2011; 17 (8):926–7. Epub 2011/08/06. nm.2443 [pii] https://doi.org/10.1038/nm.2443 PMID: 21818086.
51. Savin VJ, Sharma M, Zhou J, Gennochi D, Fields T, Sharma R, et al. Renal and Hematological Effects of CLCF-1, a B-Cell-Stimulating Cytokine of the IL-6 Family. J Immunol Res. 2015; 2015:714964. Epub 2015/07/07. https://doi.org/10.1155/2015/714964 PMID: 26146641.
52. Charba DS, Wiggins RC, Goyal M, Wharram BL, Wiggins JE, McCarthy ET, et al. Antibodies to protein tyrosine phosphatase receptor type O (PTPro) increase glomerular albumin permeability (P(alb)). Am J Physiol Renal Physiol. 2009; 297(1):F138–44. Epub 2009/05/01. 00122.2008 [pii] https://doi.org/10.1152/ajprenal.00122.2008 PMID: 19403647.
53. Musante L, Candiano G, Bruschi M, Santucci L, Carnemolla B, Orecchia P, et al. Circulating anti-actin and anti-ATP synthase antibodies identify a sub-set of patients with idiopathic nephrotic syndrome. Clin Exp Immunol. 2005; 141(3):491–9. Epub 2005/07/28. CEI2862 [pii] https://doi.org/10.1111/j.13652249.2005.02862.x PMID: 16045739.
54. Alachkar N, Gupta G, Montgomery RA. Angiotensin antibodies and focal segmental glomerulosclerosis. N Engl J Med. 2013; 368(10):971–3. Epub 2013/03/08. https://doi.org/10.1056/NEJMc1207233 PMID: 23465123.
55. Dantal J, Godfrin Y, Koll R, Perretto S, Naulet J, Bouhours JF, et al. Antihuman immunoglobulin affinity immunoadsorption strongly decreases proteinuria in patients with relapsing nephrotic syndrome. J Am Soc Nephrol. 1998; 9(9):1709–15. Epub 1998/09/04. PMID: 9727380.
56. Franco Palacios CR, Lieske JC, Wadei HM, Rule AD, Fervenza FC, Voskoboev N, et al. Urine but not serum soluble urokinase receptor (suPAR) may identify cases of recurrent FSGS in kidney transplant candidates. Transplantation. 2013; 96(4):394–9. Epub 2013/06/06. https://doi.org/10.1097/TP.0b013e3182977ab1 PMID: 23736353.
57. Xie JX, Alderson H, Ritchie J, Kalra PA, Xie Y, Ren K, et al. Circulating CD40 and sCD40L Predict Changes in Renal Function in Subjects with Chronic Kidney Disease. Sci Rep. 2017; 7(1):7942. Epub 2017/08/13. https://doi.org/10.1038/s41598-017-08426-8 PMID: 28801616.
58. Rizvi M, Pathak D, Freedman JE, Chakrabarti S. CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med. 2008; 14(12):530–8. Epub 2008/11/04. S1471-4914(08)00204-9 [pii] https://doi.org/10.1016/j.molmed.2008.09.006 PMID: 18977174.
59. Lievens D, Eijgelaar WJ, Biessen EA, Daemen MJ, Lutgens E. The multi-functionality of CD40L and its receptor CD40 in atherosclerosis. Thromb Haemost. 2009; 102(2):206–14. Epub 2009/08/05. TH09-01-0029 [pii] https://doi.org/10.1160/TH09-01-0029 PMID: 19652870.
60. Pamukcu B, Lip GY, Snezhitskiy V, Shantsila E. The CD40-CD40L system in cardiovascular disease. Ann Med. 2011; 43(5):331–40. Epub 2011/01/20. https://doi.org/10.3109/07853890.2010.546362 PMID: 21244217.
61. Korniluk A, Kemona H, Dymicka-Piekarska V. Multifunctional CD40L: pro- and anti-neoplastic activity. Tumour Biol. 2014; 35(10):9447–57. Epub 2014/08/15. https://doi.org/10.1007/s13277-014-2407-x PMID: 25117071.
62. Hassan GS, Stagg J, Mourad W. Role of CD154 in cancer pathogenesis and immunotherapy. Cancer Treat Rev. 2015; 41(5):431–40. Epub 2015/04/07. S0305-7372(15)00052-3 [pii] https://doi.org/10.1016/j.ctrv.2015.03.007 PMID: 25843228.
63. Khong A, Nelson DJ, Nowak AK, Lake RA, Robinson BW. The use of agonistic anti-CD40 therapy in treatments for cancer. Int Rev Immunol. 2012; 31(4):246–66. Epub 2012/07/19. https://doi.org/10.3109/08830185.2012.698338 PMID: 22804570.